Affimed N.V.: Fit-for-purpose ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive peripheral T cell lymphoma and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND filing exp. in 3Q19 for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
Im Neuenheimer Feld 582
Heidelberg, 69120
Germany

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Oktoberfest 2019 Wall Street "On Tap"

Munich, Germany, October 4, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.